rket, and the company's pharmaceutical business. The Cambridge, Mass.-based company offers the FoundationOne cancer panel for solid tumors and the FoundationOne Heme for blood-based cancers. Together, the tests represent "the most comprehensive set of genes and alteration types and is thus able to identify more a

ailable for patients and physicians. • New York State approval: In July, the New York State Department of Health fully approved FoundationOne and FoundationOne Heme, an important regulatory milestone. • FoundationOne CareLine: In June, the company expanded its partnership with the Patient Advocate Foundation t